MMJ’s vision is to be the international leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which addresses patients unmet medical needs.
MMJ International Holdings Corp.
MMJ International Holdings Corp., along with its subsidiary companies, is dedicated to advancing the sciences involving patient use of medical Cannabis. The MMJIH family consists of MMJ Technologies, Inc, MMJ Genomics, Inc., MMJ Health Care, Inc., MMJ Curriculum Inc., and MMJ Cultivation, Inc.
According to the American Medical Association and the American Academy of Family Practice, current methods to assess the nation’s largest and most expensive medical conditions are subjective and ineffective.
The MMJ® family has a better way, utilizing predictive analysis of genetics and other patient factors.
It is our mission to provide patients better information for better health while treating with medical cannabis, from our family to yours.
MMJ Mission and Values
Our mission is to improve the lives of patients
MMJ International Holdings aims to advance the science of medical cannabis through the establishment and operation of patient-focused business entities. We have seized the opportunity to take a scientific approach to proving the efficacy of cannabis as a medicine. This has enabled us to take advantage of cutting-edge technologies and ground-breaking opportunities available in the medical cannabis industry.
Our efforts in the United States, Canada, and Internationally, for the foreseeable future, will revolve around establishing patient clinical trial services within medical markets that can prove the efficacy of medical products being used and developed for treatment of several chronic illnesses. These proprietary extracts are already showing significant anecdotal evidence in several thousand patients currently under a treatment regime.
MMJ Genomics is leading the development of precision medicine and human genomic research. We will empower our patients through research and knowledge. We intend to remove the stigma attached to medical marijuana and broaden to treating base of patients of several chronic diseases who are unaware of the medicinal value. This is the core value that motivates our MMJ Team.
Through this subsidiary, the company will collect patient DNA from saliva samples and do genomic research to show how the RNA and proteins are altered when patients are treated with Medical Cannabis.
MMJ Technologies, Inc.
Through this subsidiary, the company has developed multiple proprietary Medical Cannabis research technologies to collect …